Levodopa and Psoriasis

Barbeau, A.; Giroux, Jean-Mario

doi:10.1016/s0140-6736(72)90600-9

Cited by 7 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Levodopa is a dopaminergic drug used as a first-line treatment option for PD (Hayes, 2019 ). Barbeau et al noticed the resolution of skin lesions in patients with PD and psoriasis treated with levodopa (Barbeau and Giroux, 1972 ). Giroux et al encouraged by these observations decided to perform their own original study where they administered levodopa with the peripheral DOPA decarboxylase inhibitor to psoriatic patients without PD.…”

Section: Discussionmentioning

confidence: 99%

“…We found four reports where resolution or improvement in psoriatic skin lesions was observed after administration of levodopa (Barbeau, 1970;Barbeau and Giroux, 1972;Giroux et al, 1972;Rojo Suárez et al, 2017). Levodopa is a dopaminergic drug used as a first-line treatment option for PD (Hayes, 2019).…”

Section: The E Cacy Of Common Drugs In the Treatment Of Psoriasis And...mentioning

confidence: 99%

See 1 more Smart Citation

Psoriasis and neurodegenerative diseases—a review

Nowowiejska

Baran

Flisiak

2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Psoriasis is a chronic skin disease with underlying genetic, inflammatory and immunological background, which is a great medical problem, currently regarded as a systemic condition. Neurodegenerative diseases (NDs) are characterized by a progressive loss of nervous tissue, which affects elderly people more frequently; therefore, it is suspected that, due to society's aging, morbidity is going to increase. We performed a thorough review in order to investigate for the first time whether psoriasis may predispose to different particular neurodegenerative diseases—Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). PubMed search resulted in the retrieval of 833 records, of which 77 eligible were included in the review. Our thorough analysis revealed there are some potential links between psoriasis and NDs (inflammation, oxidative stress, genetics, cardiometabolic disorders), but there is no strong evidence that psoriasis may predispose to NDs. Based on the evidence, it seems that the risk of PD in psoriatics is not increased, and the evidence for increased risk of AD slightly prevails the data that state the opposite. ALS risk does not seem to be increased in psoriatics. The paucity of original studies does not allow for the formulation of definitive conclusions but encourages to perform further investigations.

show abstract

Section: Discussionmentioning

confidence: 99%